Patents by Inventor Daniele Losi
Daniele Losi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110286996Abstract: The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes.Type: ApplicationFiled: August 5, 2011Publication date: November 24, 2011Applicant: Vicuron Pharmaceuticals Inc.Inventors: Enrico Selva, Flavia Marinelli, Daniele Losi, Linda Cavaletti, Ameriga Lazzarini, Alessandra Marazzi
-
Patent number: 8007789Abstract: The invention relates to antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 811112 factor A, factor B1 and factor B, which are produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and composition thereof, and their use as an antibacterial agent having activity versus susceptible microbes.Type: GrantFiled: June 26, 2008Date of Patent: August 30, 2011Assignee: Vicuron Pharmaceuticals Inc.Inventors: Enrico Selva, Flavia Marinelli, Daniele Losi, Linda Cavaletti, Ameriga Lazzarini, Alessandra Marazzi
-
Publication number: 20100197799Abstract: This invention is related to hydroxylamino derivatives of the following general formula (I) wherein n is 0, 1 or 2; R1 and R2, independently of each other, are H, OH or OCH3; R3 is H or CH3; R4 is H, C1-C3 straight or branched alkyl or, together with R3, forms a five to seven-membered carbocyclic ring; and R5 and R6, independently of each other, are H or C1-C5 straight or branched alkyl and the pharmaceutically acceptable salts or prodrug thereof, for the preparation of medicaments useful for the prevention, treatment and diagnosis of CNS degenerative disorders related to protein misfolding and/or misaggregation. The invention also relates to novel compounds included in formula (I), to a method for preparing the compounds and to pharmaceutical compositions containing them.Type: ApplicationFiled: April 14, 2010Publication date: August 5, 2010Applicants: NEWRON PHARMACEUTICALS S.P.A., VICURON PHARMACEUTICALS INCInventors: Carla CACCIA, Laura Girola, Petra Karin Kaltofen, Daniele Losi, Patricia Salvati, Enrico Selva, Florian Thaler
-
Patent number: 7763751Abstract: This invention is related to hydroxylamino derivatives of the general formula (I) wherein n is 0, 1 or 2; R1 and R2, independently of each other, are H, OH or OCH3; R3 is H or CH3; R4 is H, C1-C3 straight or branched alkyl or, together with R3, forms a five to seven-membered carbocyclic ring; and R5 and R6, independently of each other, are H or C1-C5 straight or branched alkyl and the pharmaceutically acceptable salts or prodrug thereof, for the preparation of medicaments useful for the prevention, treatment and diagnosis of CNS degenerative disorders related to protein misfolding and/or misaggregation. The invention also relates to novel compounds included in formula (I), to a method for preparing said compounds and to pharmaceutical compositions containing them.Type: GrantFiled: December 10, 2004Date of Patent: July 27, 2010Assignees: Newron Pharmaceuticals S.p.A., Vicuron Pharmaceuticals Inc.Inventors: Carla Caccia, Laura Girola, Petra Karin Kaltofen, Daniele Losi, Patricia Salvati, Enrico Selva, Florian Thaler
-
Publication number: 20090023665Abstract: The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes.Type: ApplicationFiled: June 26, 2008Publication date: January 22, 2009Applicant: Vicuron Pharmaceuticals Inc.Inventors: Enrico Selva, Flavia Marinelli, Daniele Losi, Linda Cavaletti, Ameriga Lazzarini, Alessandra Marazzi
-
Patent number: 7407654Abstract: The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes.Type: GrantFiled: October 4, 2002Date of Patent: August 5, 2008Assignee: Vicuron Pharmaceuticals, Inc.Inventors: Enrico Selva, Flavia Marinelli, Daniele Losi, Linda Cavaletti, Ameriga Lazzarini, Alessandra Marazzi
-
Patent number: 7351687Abstract: The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation of Microbispora sp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891, which is a complex comprising two Factors, denominated Factors A1 and A2, has a peptide structure containing lanthionine and methyllanthionine as constituents which are typical characteristics of the antibiotics of the lantibiotics group. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such as M. catharralis, Neisseria species and H. influenzae and Mycobacteria.Type: GrantFiled: January 26, 2005Date of Patent: April 1, 2008Assignee: Vicuron Pharmaceuticals, Inc.Inventors: Ameriga Lazzarini, Luciano Gastaldo, Gianpaolo Candiani, Ismaela Ciciliato, Daniele Losi, Flavia Marinelli, Enrico Selva, Franco Parenti
-
Patent number: 7319088Abstract: The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation of Microbispora sp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891, which is a complex comprising two Factors, denominated Factors A1 and A2, has a peptide structure containing lanthionine and methyllanthionine as constituents which are typical characteristics of the antibiotics of the lantibiotics group. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such as M. catharralis, Neisseria species and H. influenzae and Mycobacteria.Type: GrantFiled: January 12, 2005Date of Patent: January 15, 2008Assignee: Vicuron Pharmaceuticals Inc.Inventors: Ameriga Lazzarini, Luciano Gastaldo, Gianpaolo Candiani, Ismaela Ciciliato, Daniele Losi, Flavia Marinelli, Enrico Selva, Franco Parenti
-
Patent number: 7307057Abstract: The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation of Microbispora sp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such as M. catharralis, Neisseria species and H. influenzae and Mycobacteria.Type: GrantFiled: July 12, 2004Date of Patent: December 11, 2007Assignee: Naicons S.C.A.R.L.Inventors: Ameriga Lazzarini, Luciano Gastaldo, Gianpaolo Candiani, Ismaela Ciciliato, Daniele Losi, Flavia Marinelli, Enrico Selva, Franco Parenti
-
Publication number: 20070049643Abstract: This invention is related to hydroxylamino derivatives of the general formula (I) wherein n is 0, 1 or 2; R1 and R2, independently of each other, are H, OH or OCH3; R3 is H or CH3; R4 is H, C1-C3 straight or branched alkyl or, together with R3, forms a five to seven-membered carbocyclic ring; and R5 and R6, independently of each other, are H or C1-C5 straight or branched alkyl and the pharmaceutically acceptable salts or prodrug thereof, for the preparation of medicaments useful for the prevention, treatment and diagnosis of CNS degenerative disorders related to protein misfolding and/or misaggregation. The invention also relates to novel compounds included in formula (I), to a method for preparing said compounds and to pharmaceutical compositions containing them.Type: ApplicationFiled: December 10, 2004Publication date: March 1, 2007Inventors: Carla Caccia, Laura Girola, Petra Kaltofen, Daniele Losi, Patricia Salvati, Enrico Selva, Florian Thaler
-
Publication number: 20060183673Abstract: The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation of Microbispora sp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891, which is a complex comprising two Factors, denominated Factors A1 and A2, has a peptide structure containing lanthionine and methyllanthionine as constituents which are typical characteristics of the antibiotics of the lantibiotics group. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such as M. catharralis, Neisseria species and H. influenzae and Mycobacteria.Type: ApplicationFiled: July 12, 2004Publication date: August 17, 2006Applicant: VICURON PHARMACEUTICALS INC.Inventors: Ameriga Lazzarini, Luciano Gastaldo, Gianpaolo Candiani, Ismaela Ciciliato, Daniele Losi, Flavia Marinelli, Enrico Selva, Franco Parenti
-
Publication number: 20050233952Abstract: The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation of Microbispora sp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891, which is a complex comprising two Factors, denominated Factors A1 and A2, has a peptide structure containing lanthionine and methyllanthionine as constituents which are typical characteristics of the antibiotics of the lantibiotics group. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such as M. catharralis, Neisseria species and H. influenzae and Mycobacteria.Type: ApplicationFiled: January 26, 2005Publication date: October 20, 2005Applicant: VICURON PHARMACEUTICALS INC.Inventors: Ameriga Lazzarini, Luciano Gastaldo, Gianpaolo Candiani, Ismaela Ciciliato, Daniele Losi, Flavia Marinelli, Enrico Selva, Franco Parenti
-
Publication number: 20050203005Abstract: The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation of Microbispora sp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891, which is a complex comprising two Factors, denominated Factors A1 and A2, has a peptide structure containing lanthionine and methyllanthionine as constituents which are typical characteristics of the antibiotics of the lantibiotics group. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such as M. catharralis, Neisseria species and H. influenzae and Mycobacteria.Type: ApplicationFiled: January 12, 2005Publication date: September 15, 2005Applicant: VICURON PHARMACEUTICALS INC.Inventors: Ameriga Lazzarini, Luciano Gastaldo, Gianpaolo Candiani, Ismaela Ciciliato, Daniele Losi, Flavia Marinelli, Enrico Selva, Franco Parenti
-
Publication number: 20050020514Abstract: The invention relates to an antibiotic substances of microbial origin, arbitrarily denominated antibiotic GE 81112 factor A, factor B1 and factor B, which is produced by fermentation of Streptomyces sp. DSMZ 14386, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes.Type: ApplicationFiled: October 4, 2002Publication date: January 27, 2005Inventors: Enrico Selva, Flavia Marinelli, Daniele Losi, Linda Cavaletti, Ameriga Lazzarini, Alessandra Marazzi